Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2019 Earnings Results

Madrigal Pharmaceuticals Reports Q1 2019 Earnings, Stock Up 0.66%

Madrigal Pharmaceuticals reported a loss of $0.98 per share, with no revenue figures disclosed. The stock reacted positively, rising 0.66%, likely due to investor optimism about ongoing clinical trials and product development despite the lack of detailed financial guidance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.98	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Neutral

Management emphasized their ongoing commitment to research and development. There was no specific guidance provided for future earnings.

Management did not provide specific revenue guidance for the upcoming quarters.

The focus remains on advancing clinical trials and product development.

Madrigal Pharmaceuticals Reports Q1 2019 Earnings, Stock Up 0.66%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Reports Q1 2019 Earnings, Stock Up 0.66%

Key numbers

Management commentary